Trial · NCT06390904
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
NCT06390904, Phase 2, Phase 3, Active not recruiting, Xiaojun Chen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients. Trials, record NCT06390904. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06390904
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
- NCT number
- NCT06390904
- Status
- Active not recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 29 participants, estimated
- Lead sponsor
- Xiaojun Chen
- Conditions
- Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Interventions
- GnRH antagonist, Letrozole 2.5mg
- First posted
- 2024-04-30
- Last updated
- 2025-08-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response (CR) rate within 28 weeks of treatment | Up to 28 weeks | The cumulative 28-week CR rate will be calculated. Patients will be evaluated with an hysteroscopy every 12 to 16 weeks. The response to progestin treatment was assessed histologically using specimens obtained during each hysteroscopic evaluation. CR was defined as the absence of hyperplasia or carcinoma. |
| Secondary | Adverse events | During the treatment period, an average of 28 weeks | Adverse effects were recorded during the entire treatment period, including weight gain, thrombosis, lactic acidosis, abnormal liver and renal function, and other toxicities or complaints. |
| Secondary | Time to achieve CR | During the treatment period, an average of 28 weeks | The median CR time will be calculated. |
| Secondary | Relapse rate | Average of 2 years after the completion of the treatment | Relapse will be defined as endometrial hyperplasia or endometrial cancer recurred after patients achieve CR. |
| Secondary | Rate of fertility outcomes | Average of 2 years after the completion of the treatment | Among patients prepared to get pregnant, fertility outcomes will be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34085795 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06390904
GET https://conductscience.org/api/trials/v1/NCT06390904/registered